Nationwide Recall Issued for Injectable Wellness Products Over Elevated Endotoxin Levels

Several injectable products distributed across the United States are being recalled after a compounding company discovered that an ingredient used in their preparation contained elevated levels of endotoxins.

Centric Compounding LLC, a Houston-based compounding company, is voluntarily recalling six lots of three injectable products: compounded glutathione, Myer’s Cocktail, and Tri-Immune Boost. The U.S. Food and Drug Administration published the company’s recall notice on Sept. 13, 2026, after the company announced the recall.

The products were distributed nationwide to patients through home delivery and to prescribers. Centric says it has also received nine reports involving symptoms that may have occurred after use of the affected products.

Reported symptoms included fever, chills, chest pain, nausea or vomiting, headache, and malaise, which refers to a general feeling of discomfort or illness. The company is advising consumers who have recalled products to immediately stop using them and dispose of the affected vials.

Which Products Are Included?

The recall involves three injectable preparations supplied in 30 milliliter multidose vials.

The affected glutathione product has a concentration of 200 milligrams per milliliter. Three lots are included in the recall:

• Lot 062326:B, with a beyond-use date of Aug. 7, 2026
• Lot 070826:A, with a beyond-use date of Aug. 22, 2026
• Lot 072726:D, with a beyond-use date of Sept. 25, 2026

Two lots of Myer’s Cocktail are also being recalled:

• Lot 070226:D, with a beyond-use date of Aug. 16, 2026
• Lot 072126:A, with a beyond-use date of Sept. 4, 2026

The sixth recalled product is Tri-Immune Boost, lot 071626:B, which carries a beyond-use date of Aug. 30, 2026.

Consumers who have these products should compare the lot number and date on their vial with the information in the official recall notice rather than relying only on the product name.

Why Were the Products Recalled?

According to the FDA notice, the recalled preparations were made using a glutathione active pharmaceutical ingredient that was found to contain elevated endotoxin levels.

Endotoxins are substances associated with the outer membranes of certain bacteria. When introduced directly into the body, particularly through an injection, elevated levels can trigger significant inflammatory reactions.

The FDA's recall notice states that injectable products containing elevated endotoxin levels could potentially cause serious medical events, including fever, low blood pressure, inflammatory reactions, anaphylactic shock, and death.

The warning does not mean that every person who received one of the recalled products will experience a serious complication. However, because injections can introduce a substance directly into the body, the potential presence of elevated endotoxin levels is considered a significant quality and safety concern.

What Should Consumers Do?

Centric Compounding is telling consumers to stop using any affected products and discard the recalled vials.

The company says it is contacting distributors and customers by email and arranging replacement products. Anyone who believes they experienced a health problem after receiving one of the recalled injections should contact a physician or another qualified health care professional.

People who currently have a vial of glutathione, Myer’s Cocktail, or Tri-Immune Boost should first check whether the product is among the recalled lots. The FDA has published the complete lot information as part of its recall announcement.

Consumers with questions about the recall can contact Centric Compounding at 833-777-6664 or info@centriccompounding.com. The company lists its consumer contact hours as Monday through Friday, from 9 a.m. to 5 p.m. Central Time.

Patients and health professionals can also report suspected adverse reactions or product quality concerns through the FDA's MedWatch reporting system.

What Are Compounded Drugs?

The recall also highlights the importance of quality control in compounded medications.

Compounded drugs are prepared by pharmacies or other authorized facilities to meet specific patient needs. They can play an important role when an appropriate commercially manufactured medication is unavailable or unsuitable for an individual patient.

However, compounded drugs are generally not subjected to the same premarket approval process as commercially manufactured drugs. The FDA has previously noted that compounded medicines can provide important treatment options while also presenting particular safety and quality risks.

The agency maintains a public database of recalls, market withdrawals, and safety alerts involving FDA-regulated products. Its current recall listings identify the Centric Compounding action as a drug recall involving elevated endotoxin levels.

Another Recent Medication Recall

The Centric Compounding recall comes amid a series of drug safety actions announced by federal regulators.

The FDA's drug recall database also lists several other recent medication recalls, including a recall involving certain thyroid tablets because of the potential for the products to be superpotent. Other recent actions have involved injectable medications affected by particulate matter or concerns involving sterility assurance.

These separate recalls involve different companies and products and should not be interpreted as being connected to the Centric Compounding action.

For consumers, the key lesson is to pay attention to specific lot numbers and recall instructions. A recall generally applies to particular batches rather than necessarily every product manufactured by a company.

What Happens Next?

Centric Compounding says it is working with distributors and customers to remove the affected products from use and provide replacements. The FDA has stated that the recall is being conducted with the agency's knowledge.

People who may have received an affected injection should not ignore symptoms that could indicate a serious reaction. Anyone experiencing significant or rapidly worsening symptoms should seek appropriate medical attention.

Consumers should also avoid making treatment decisions based solely on online reports or news coverage. A health care professional can provide individualized guidance based on the product received, the date it was administered, the person's medical history, and any symptoms that have developed.

Source

U.S. Food and Drug Administration's Sept. 13, 2026.

Disclaimer

This article is provided for general informational purposes only and is not medical advice. It should not be used to diagnose, treat, or prevent any medical condition. People who have used a recalled product or who are experiencing symptoms should contact a qualified health care professional for individualized advice. In an emergency or if severe symptoms occur, seek immediate medical attention.